Common use of No Safety Notices Clause in Contracts

No Safety Notices. (a) There have been no recalls, field notifications, field corrections, market withdrawals or replacements, warnings, “dear doctor” letters, investigator notices, safety alerts or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Company’s products (“Safety Notices”), except as would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Change, and (B) to the knowledge of the Company, there are no facts that would be reasonably likely to result in (1) a Safety Notice with respect to the Company’s products, (2) a material change in labeling of any of the Company’s products, or (3) a termination or suspension of marketing or testing of any of the Company’s products, except, in each of cases (1), (2) or (3) such as would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Change.

No Safety Notices. (ai) There have been no recalls, field notifications, field corrections, market withdrawals or replacements, warnings, “dear doctor” letters, investigator notices, safety alerts or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Company’s products (“Safety Notices”), except as would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse ChangeEffect, and (Bii) to the knowledge of the Company’s knowledge, there are no facts that would be reasonably likely to result in (1x) a Safety Notice with respect to the Company’s productsproducts or services, (2y) a material change in labeling of any of the Company’s products, or (3z) a termination or suspension of marketing or testing of any of the Company’s products, except, in each of cases (1x), (2y) or (3z) such as would not, singly or in the aggregate, not reasonably be expected to result in have a Material Adverse ChangeEffect.

No Safety Notices. (ai) There Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there have been no recalls, field notifications, field corrections, market withdrawals or replacements, warnings, “dear doctor” letters, investigator notices, safety alerts or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Company’s products (“Safety Notices”), except as would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Change, ) and (Bii) to the knowledge of the Company’s knowledge, there are no facts that would be reasonably likely to result in (1x) a Safety Notice with respect to the Company’s productsproducts or services, (2y) a material change in labeling of any of the Company’s productsrespective products or services, or (3z) a termination or suspension of marketing or testing of any of the Company’s productsproducts or services, except, in each of cases (1), (2) or (3) such except as would notnot reasonably be expected, singly individually or in the aggregate, reasonably be expected to result in a Material Adverse ChangeEffect.

No Safety Notices. Except as would not, singly or in the aggregate, have a Material Adverse Effect: (ai) There there have been no recalls, field notifications, field corrections, market withdrawals or replacements, warnings, “dear doctor” letters, investigator notices, safety alerts or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Company’s or its subsidiaries’ products or services (collectively, “Safety Notices”), except as would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Change, ) and (Bii) to the knowledge of the Company, there are no facts that would be reasonably likely to result in (1x) a Safety Notice with respect to the Company’s productsor its subsidiaries’ products or services, or (2y) a material change in labeling of any of the Company’s products, or its subsidiaries’ products or (3z) a termination or suspension of marketing marketing, testing or testing distribution of any of the Company’s products, except, in each of cases (1), (2) or (3) such as would not, singly its subsidiaries’ products or in the aggregate, reasonably be expected to result in a Material Adverse Changeservices.